Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Amgen    AMGN

AMGEN (AMGN)
Mes dernières consult.
Most popular
  Report  
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
 Analysis summary4-Traders Strategies
Summary
  • In a short-term perspective, the company has interesting fundamentals.
Strengths
  • Margins returned by the company are among the highest on the stock exchange list. Its core activity clears big profits.
  • Thanks to a sound financial situation, the firm has significant leeway for investment.
  • Analysts remain confident with respect to the group's activity and, more often than not, have revised upwards their earnings per share estimates.
  • For the last twelve months, analysts have been gradually revising upwards their EPS forecast for the upcoming fiscal year.
Weaknesses
  • Stock prices approach a strong long-term resistance in weekly data at USD 196.01.
  • The stock is close to a major daily resistance at USD 198, which should be gotten rid of so as to gain new appreciation potential.
  • According to Thomson-Reuters' forecast, revenue growth prospects are expected to be very low for the next fiscal years.
  • The company's "enterprise value to sales" ratio is among the highest in the world.
Ratings chart
Sector Pharmaceuticals - NEC
1st jan.Capitalisation (M$)Investor Rating
AMGEN12.66%129 635
JOHNSON & JOHNSON-8.56%337 763
PFIZER3.59%219 534
NOVARTIS-3.93%201 464
ROCHE HOLDING LTD.-5.60%200 973
MERCK AND COMPANY11.76%169 193
ABBOTT LABORATORIES9.94%110 556
SANOFI0.08%104 948
GLAXOSMITHKLINE19.17%103 431
BAYER-8.75%101 760
ELI LILLY AND COMPANY6.22%97 374
NOVO NORDISK A/S-5.31%94 989
BRISTOL-MYERS SQUIBB COMPAN..-7.29%92 940
ASTRAZENECA7.44%92 021
CELGENE CORPORATION-17.89%62 110
ALLERGAN PLC7.91%60 065
More Results
Financials ($)
Sales 2018 22 712 M
EBIT 2018 11 648 M
Net income 2018 8 740 M
Finance 2018 10 236 M
Yield 2018 2,65%
P/E ratio 2018 15,69
P/E ratio 2019 14,87
EV / Sales 2018 5,26x
EV / Sales 2019 5,21x
Capitalization 130 B
Surperformance© ratings
  Help  
Fundamental ratings
Overall rating
Trading Rating
Investor Rating
Growth (Revenue)
Valuation
Finances
Profitability
Earnings quality
Business Predictability
P/E ratio
Potential
Yield
Consensus
7 days EPS revision
4 months EPS revision
1 year EPS revision
4 months Revenue revision
1 year Revenue revision
Technical ratings
Short Term Timing
Middle Term Timing
Long Term Timing
RSI
Bollinger Spread
Unusual Volumes
Chart AMGEN
Duration : Period : Day
Amgen Technical Analysis Chart | AMGN | US0311621009 | 4-Traders
Duration : Period : Week
Amgen Technical Analysis Chart | AMGN | US0311621009 | 4-Traders